Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Longitudinal detection of circulating tumor DNA in patients with advanced renal cell carcinoma.

ctDNA was detected at any time point in 70% (29/41). All 14 patients who progressed had ctDNA detected ahead of radiographic progression (100% sensitivity in this series) with a median lead time of 13.6 weeks (range 1-39.7). Concordance between clinical outcome and ctDNA status was 78% (32/41).

ASCO Genitourinary Cancers Symposium 2023PubMed 39693589